EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

Five‐Year Outcomes With Delandistrogene Moxeparvovec in Patients With Duchenne Muscular Dystrophy: A Phase 1/2a Study

Jerry R Mendell iD, Zarife Sahenk iD, Linda P Lowes iD, Megan A Iammarino iD, Lindsay N Alfano iD, Craig M McDonald iD, James E Signorovitch iD, Jim Jin, Jing Li, Stefanie Mason iD, Louise R Rodino-Klapac iD

Muscle & Nerve · 2026

DOI: 10.1002/mus.70276 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Muscle & Nerve, 2026. Verfasst von Jerry R Mendell und 10 weiteren Autor:innen. Beteiligte Einrichtung: Jerry Mendell Center for Gene Therapy, Nationwide Children's Hospital, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Genetic Therapy, Recombinant Fusion Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sarepta Therapeutics Inc., Nationwide Children's Foundation, Parent Project Muscular Dystrophy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

We report 5‐year results from a phase 1/2a study of delandistrogene moxeparvovec, a recombinant adeno‐associated virus serotype rh74 vector‐based gene therapy for Duchenne muscular dystrophy (DMD), with post hoc analyses contextualizing functional outcomes.

Methods

Four ambulatory patients with DMD (≥ 4–< 8 years at enrollment) entered an open‐label trial (Study 101; NCT03375164), receiving a single intravenous dose of delandistrogene moxeparvovec (2.0 × 10 14 vg/kg by supercoiled quantitative polymerase chain reaction (qPCR), equivalent to 1.33 × 10 14 vg/kg by linear qPCR). Safety and functional outcomes (including North Star Ambulatory Assessment [NSAA] total score, time to rise [TTR] from floor, 10‐m walk/run [10MWR] time) were assessed. In post hoc analyses, functional outcomes of delandistrogene moxeparvovec–treated patients were compared with propensity‐score‐weighted external controls (ECs) and natural history predictions.

Results

No new safety signals were reported 5 years post‐infusion. One patient had cardiomyopathy at year 5; however, this event was deemed unrelated to treatment. All delandistrogene moxeparvovec–treated patients (mean age, 10.2 years) remained ambulant. The 5‐year NSAA total score mean change from baseline (standard deviation) for treated patients versus ECs was +7.5 (2.4) versus −3.9 (2.9) (least‐squares mean between‐group difference [standard error]: 9.8 [3.5], p = 0.0127). TTR and 10MWR mean times were stable, representing clinically meaningful differences versus ECs. An increased divergence in NSAA total score from 5‐year natural history predictions favoring gene therapy was also seen.

Discussion

Findings support the long‐term, manageable safety profile of delandistrogene moxeparvovec in ambulatory patients with appropriate monitoring and demonstrate stabilization or delayed disease progression with treatment compared with matched untreated ECs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneGenetic TherapyRecombinant Fusion ProteinsHumansMaleTreatment OutcomeChildChild, PreschoolGene Therapy AgentsDependovirus

Stichwörter der Autor:innen

Duchenne muscular dystrophydelandistrogene moxeparvovecgene therapymicro‐dystrophinrAAVrh74

Substanzen

Recombinant Fusion Proteinsdelandistrogene moxeparvovec

Autor:innen und Institutionen

  • Jerry Mendell Center for Gene Therapy, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Department of Pediatrics, The Ohio State University, Columbus, Ohio, USA.
  • Sarepta Therapeutics Inc., Cambridge, Massachusetts, USA.
  • Departments of Physical Medicine & Rehabilitation and Pediatrics, University of California Davis Health, Sacramento, California, USA.
  • Analysis Group Inc, Boston, Massachusetts, USA.

ORCID-Profile: Jerry R Mendell, Zarife Sahenk, Linda P Lowes, Megan A Iammarino, Lindsay N Alfano, Craig M McDonald, James E Signorovitch, Stefanie Mason, Louise R Rodino-Klapac

Förderung

  • Sarepta Therapeutics Inc.
  • Nationwide Children's Foundation
  • Parent Project Muscular Dystrophy
  • Sarepta Therapeutics

Zitieren

APA

Mendell, J. R., Sahenk, Z., Lowes, L. P., Iammarino, M. A., Alfano, L. N., McDonald, C. M., Signorovitch, J. E., Jin, J., Li, J., Mason, S., & Rodino-Klapac, L. R. (2026). Five‐Year Outcomes With Delandistrogene Moxeparvovec in Patients With Duchenne Muscular Dystrophy: A Phase 1/2a Study. Muscle & Nerve. https://doi.org/10.1002/mus.70276

Vancouver

Mendell JR, Sahenk Z, Lowes LP, Iammarino MA, Alfano LN, McDonald CM, et al. Five‐Year Outcomes With Delandistrogene Moxeparvovec in Patients With Duchenne Muscular Dystrophy: A Phase 1/2a Study. Muscle & Nerve. 2026. doi:10.1002/mus.70276

BibTeX
@article{Mendell2026,
  author = {Mendell, Jerry R and Sahenk, Zarife and Lowes, Linda P and Iammarino, Megan A and Alfano, Lindsay N and McDonald, Craig M and Signorovitch, James E and Jin, Jim and Li, Jing and Mason, Stefanie and Rodino-Klapac, Louise R},
  title = {Five‐Year Outcomes With Delandistrogene Moxeparvovec in Patients With Duchenne Muscular Dystrophy: A Phase 1/2a Study},
  journal = {Muscle & Nerve},
  year = {2026},
  doi = {10.1002/mus.70276}
}
Kostenlos starten →